Program
XNW5004
A development code. Also written as “XNW5004 tablets”, “XNW5004 combined with CHOEP (incremental)” and “XNW5004 combined with CHOP (extended)”.
Its studies are mostly in Prostatic Neoplasms · Lymphoma, T-Cell, Peripheral · Lymphoma · Squamous Cell Carcinoma of Head and Neck · Lymphoma, Follicular, led by Evopoint Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Evopoint Biosciences | 75 open or running | phase 2since Aug 17, 2023 | Aug 17, 2023 | Jan 2027phase 2 · NCT06702605 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2023First study: phase 2 study in CarcinomaFirst studyNCT06022757 · 12 enrolled · China
- Aug 14, 2024Phase 2 study in LymphomaNCT06558513 · 120 enrolled · China
- Nov 11, 20242 phase 2 studiesNCT06702995, NCT06702605
- Mar 26, 2026Phase 2 study in Lymphoma, FollicularNCT07545603 · 65 planned · China
- Jul 8, 20262 phase 2 studiesNCT07730515, NCT07730580
- Oct 20, 2026Primary completion moved from 2026-05-13 to 2027-07-13Date moved laterphase 2 · +14 months · NCT06702995
Ahead
- Jan 2027Primary completion: phase 2 study in Lymphoma, T-Cell, PeripheralNCT06702605
- Jul 13, 2027Primary completion: phase 2 study in Metastatic Castrate-Resistant Prostate CancerNCT06702995
- Dec 31, 2027Primary completion: phase 2 study in Lymphoma, FollicularNCT07545603
- Sep 30, 2028Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07730515
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07730580Advanced Prostate Cancer | 2 | Not yet recruiting | Dec 31, 2028 | 242 |
| NCT07730515Lymphoma, Non-Hodgkin · China | 2 | Recruiting | Sep 30, 2028 | 176 |
| NCT07545603Lymphoma, Follicular · China | 2 | Recruiting | Dec 31, 2027 | 65 |
| NCT06702605Lymphoma, T-Cell, Peripheral | 2 | Not yet recruiting | Jan 2027 | 50 |
| NCT06702995Metastatic Castrate-Resistant Prostate Cancer · China | 2 | Recruiting | Jul 13, 2027 | 307 |
| NCT06558513Lymphoma · China | 2 | Completed | Aug 30, 2025 | 120 |
| NCT06022757Carcinoma · China | 2 | Terminated | Jan 13, 2025 | 12 |
How it is read
Names in the registry
- “XNW5004 tablets”, 3 entries
- “XNW5004”, 2 entries
- “XNW5004 combined with CHOEP (incremental)”, 1 entry
- “XNW5004 combined with CHOP (extended)”, 1 entry
- “XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone”, 1 entry
Codes read as this program: XNW5004.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
- Lymphoma, T-Cell, Peripheral, 2 studies
- Lymphoma, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.